CagriSema Dosage in 2026: What Clinicians Actually Prescribe

CagriSema at a glance:

• Drug class: Combination amylin analog (cagrilintide) + GLP-1 agonist (semaglutide)
• Manufacturer: Novo Nordisk
• Route: subcutaneous injection (combined formulation)
• Typical frequency: once weekly
• Half-life: approximately 7 days for both components
• Receptor target: amylin and GLP-1 receptors

Most people who quit CagriSema do it during titration, and most of those quits trace to dosing decisions. Get the schedule right and the rest is much easier.

Standard Dosing Schedule for CagriSema

Phase 3 trials use 2.4 mg of each component weekly. Not commercially available pending regulatory submission.

The typical schedule for CagriSema is once weekly via subcutaneous injection (combined formulation). Half-life of approximately 7 days for both components explains why this schedule works — the drug stays active long enough to support that interval.

Titration: Why Starting Low Matters

For incretin therapies, gradual titration is the standard approach. The starting doses listed above are not therapeutic — they exist to let the body adapt and to reduce gastrointestinal symptoms (nausea, vomiting, diarrhea).

A typical titration plan for CagriSema holds each dose step for at least four weeks before moving up. Faster titration is associated with more dropouts due to side effects.

Missed Doses

If a dose of CagriSema is missed: for weekly schedules, the rule of thumb is to take it as soon as remembered if within a defined window, otherwise skip it and resume the regular schedule. The exact window depends on the half-life (approximately 7 days for both components) and the specific product label. Never double up to make up for a missed dose.

Dose Adjustments

Dose adjustments may be needed for the following:

• Significant weight loss or weight gain
• Side-effect intolerance at the current step
• Changes in renal or hepatic function
• Drug interactions (particularly relevant for any concurrent medications)

We cover the side-effect side of dose decisions in CagriSema side effects and the cost angle of dose escalation in CagriSema cost.

What the Trials Used

Published trial data for CagriSema comes primarily from: REDEFINE 1 (Garvey 2025) — 22.7% mean weight loss at 68 weeks.

That data drives the labeled dosing range, which is what physicians prescribe by.

Special Populations

The dosing guidance above applies to general adult use. Special populations — pregnancy, pediatric, severe renal impairment, hepatic dysfunction, elderly with frailty — require individualized assessment that this page can't substitute for.

For CagriSema: the standard contraindications for this drug class apply.

Bottom Line

Dosing CagriSema is a long game. Get the titration right, hold steady, and adjust deliberately based on how your body responds.

Frequently Asked Questions

Related Reading

• CagriSema: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• CagriSema Side Effects in 2026: Real Reports, Real Solutions
• What Results Should You Expect from CagriSema? A Practical Guide
• The Real CagriSema Price Tag in 2026 — With and Without Insurance
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Frias JP et al. Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 mg with Once-Weekly Semaglutide 2.4 mg. Lancet 2021;397:1736.
• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.

This page is informational only and is not medical advice. Always follow your prescribing clinician's dosing instructions.